Necroptosis in the sarcoma immune microenvironment: From biology to therapy

Int Immunopharmacol. 2023 Sep:122:110603. doi: 10.1016/j.intimp.2023.110603. Epub 2023 Jul 17.

Abstract

Apoptosis resistance remains a major obstacle to treatment failure in sarcoma. Necroptosis is a caspase-independent programmed cell death, investigated as a novel strategy to eradicate anti-apoptotic tumor cells. The process is mediated by the receptor-interacting proteins kinase family and mixed lineage kinase domain-like proteins, which is morphologically similar to necrosis. Recent studies suggest that necroptosis in the tumor microenvironment has pro- or anti-tumor effects on immune response and cancer development. Necroptosis-related molecules display a remarkable value in prognosis prediction and therapeutic response evaluation of sarcoma. Furthermore, the induction of tumor necroptosis has been explored as a feasible therapeutic strategy against sarcoma and to synergize with immunotherapy. This review discusses the dual roles of necroptosis in the immune microenvironment and tumor progression, and explores the potential of necroptosis as a new target for sarcoma treatment.

Keywords: Anti-tumor immunity; Immunotherapy; Metastasis; Necroptosis; Sarcoma; Target therapy.

Publication types

  • Review

MeSH terms

  • Apoptosis
  • Biology
  • Humans
  • Necroptosis*
  • Necrosis / pathology
  • Receptor-Interacting Protein Serine-Threonine Kinases / metabolism
  • Sarcoma* / therapy
  • Tumor Microenvironment

Substances

  • Receptor-Interacting Protein Serine-Threonine Kinases